Arbutus Biopharma, founded in Warminster, Pennsylvania, is a publicly-traded biopharmaceutical company (NASDAQ: ABUS) committed to discovering, developing, and commercializing a cure for chronic hepatitis B infection. The company focuses on virology and aims to address unmet medical needs through its innovative portfolio of clinical assets. Arbutus leverages its expertise to develop treatments that can significantly impact patients suffering from liver diseases caused by the hepatitis B virus (HBV).
Notable affiliated individuals include experienced scientists and industry leaders who drive the company's research and development efforts. Arbutus has garnered attention from prominent investors in the biotech sector, reflecting confidence in its mission and potential. Key achievements include advancing multiple candidates in their virology pipeline to clinical stages, demonstrating significant progress toward their goal of curing hepatitis B. The overall impact of Arbutus Biopharma lies in its potential to transform the lives of millions affected by chronic hepatitis B, addressing a critical global health challenge.
